QBD-BASED RP-UPLC METHOD DEVELOPMENT AND VALIDATION FOR THE SIMULTANEOUS ESTIMATION OF ATEZOLIZUMAB AND HYALURONIDASE IN CANCER DRUG FORMULATIONS

KONDURI JAYA SREE; RAJU MUDHULKAR; SREEDHAR GUNDEKARI; NAVEEN KUMAR KOTTAKKI; AMRUTHA SRI KONDURI

doi:10.22159/ijap.2025v17i5.54200

Authors

KONDURI JAYA SREE Department of Chemistry, Koneru Lakshmaiah Education Foundation, Bowrampet, Hyderabad-500043, Telangana, India https://orcid.org/0009-0005-7092-1459
RAJU MUDHULKAR Department of Chemistry, Koneru Lakshmaiah Education Foundation, Bowrampet, Hyderabad-500043, Telangana, India https://orcid.org/0000-0002-4586-8749
SREEDHAR GUNDEKARI Department of Chemistry, Koneru Lakshmaiah Education Foundation, Bowrampet, Hyderabad-500043, Telangana, India https://orcid.org/0000-0002-5891-058X
NAVEEN KUMAR KOTTAKKI Imptech Scientific, Hyderabad-500016, Telangana, India https://orcid.org/0000-0001-5996-5366
AMRUTHA SRI KONDURI Imptech Scientific, Hyderabad-500016, Telangana, India https://orcid.org/0009-0005-6543-033X

DOI:

https://doi.org/10.22159/ijap.2025v17i5.54200

Keywords:

Hyaluronidase, Atezolizumab, Lung cancer drugs, Quality by design, UPLC, Ultra performance liquid chromatography

Abstract

Objective: Atezolizumab and hyaluronidase have been approved for subcutaneous injection for all adult indications as the intravenous formulation of atezolizumab, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS). In this study, a new reverse-phase ultra-performance liquid chromatography (RP-UPLC) method was developed using a Quality by Design (QbD) approach for the simultaneous quantification of hyaluronidase (HYAL) and atezolizumab (ATEZ).

Methods: The method optimisation was performed using a central composite design (CCD) in Design Expert Software, which offers a systematic framework for design of experiments (DOE), facilitating the evaluation of factor-response relationships and ensuring statistically significant results to enhance analytical quality. HYAL and ATEZ were successfully separated using a Waters ACQUITY UPLC HSS C₁₈ Column (100 mm × 2.1 mm, 1.8 µm particle size) with an isocratic mobile phase consisting of trifluoroacetic acid buffer (pH 2.0) and acetonitrile in a 58:42% v/v ratio, at a flow rate of 0.3 ml/min.

Results: In the developed UPLC method, HYAL and ATEZ were detected at 210 nm and 280 nm, respectively. The process was validated in compliance with ICH Q2 (R2) guidelines by evaluating key parameters such as system suitability, linearity, accuracy, precision, robustness, sensitivity, limit of detection (LOD), limit of quantification (LOQ) and analyte stability. The LOD and LOQ were determined using signal-to-noise ratios of 3:1 and 10:1, respectively, yielding values of 0.002 µg/ml (LOD) and 0.006 µg/ml (LOQ) for HYAL and 1.49 µg/ml (LOD) and 4.52 µg/ml (LOQ) for ATEZ, respectively. System suitability results demonstrated excellent reproducibility, with mean% RSD for the theoretical plate number and tailing factor across six replicate injections being 0.39% and 1.98% for HYAL and 0.22% and 0.38% for ATEZ, respectively.

Conclusion: The QbD-based RP-UPLC method developed using central composite design enables precise, sensitive, and robust simultaneous quantification of atezolizumab and hyaluronidase. The technique showed efficient separation, excellent system suitability, and low LOD and LOQ values. Validation as per ICH Q2(R2) confirms its applicability for routine analysis and quality control of ATEZ-and HYAL-loaded nano-hydrogel formulations prepared by ionic gelation.

References

1. Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A. New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 2017 Jun 2;24(6):233-43. doi: 10.1038/cgt.2017.16, PMID 28574057.

2. World Health Organization. Lung Cancer; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/lung-cancer.

3. World Heart Federation. Tobacco; 2023. Available from: https://world-heart-federation.org/what-we-do/tobacco. [Last accessed on 17 Jul 2025].

4. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014 Aug 14;14(8):535-46. doi: 10.1038/nrc3775, PMID 25056707.

5. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of American pathologists International Association for the study of Lung Cancer and Association for Molecular Pathology. J Thorac Oncol. 2013 Jul;8(7):823-59. doi: 10.1097/JTO.0b013e318290868f, PMID 23552377.

6. McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749-57. doi: 10.1038/s41591-018-0053-3, PMID 29867230.

7. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O. Atezolizumab an anti-programmed death ligand 1 antibody in metastatic renal cell carcinoma: long-term safety, clinical activity and immune correlates from a phase Ia study. J Clin Oncol. 2016 Mar;34(8):833-42. doi: 10.1200/JCO.2015.63.7421, PMID 26755520.

8. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018 Jun 14;378(24):2288-301. doi: 10.1056/NEJMoa1716948, PMID 29863955.

9. US Food and Drug Administration. FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection; 2024. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fdaapproves-atezolizumab-and-hyaluronidase-tqjs-subcutaneous-injection.

10. Bodke SS, Bhangale CJ, Bhandare SN. Stability indicating UPLC method for estimation of benazepril and hydrochlorothiazide in bulk and combined dosage form. Int J Pharm Pharm Sci. 2024;16(1):22-9. doi: 10.22159/ijpps.2024v16i1.49457.

11. Bhattacharya K, Randhoni Chanu N, Bhattacharjee A, Jyoti Sahariah B, Melody Devi C, Bordoloi R. Ultra-performance liquid chromatography an updated review. Res J Pharm Technol. 2022 Jan;15(12):5849-53. doi: 10.52711/0974-360X.2022.00987.

12. Eluru A, Babu KS. A new RP-UPLC method for the separation and simultaneous quantification of dorzolamide HCl and timolol maleate. Int J App Pharm. 2024 Apr;16(3):244-50. doi: 10.22159/ijap.2024v16i3.49491.

13. Chaitanya SM, Nissankararao S, Gandham SL. A new NP-UPLC method for the separation and simultaneous quantification of ramucirumab and erlotinib. Int J App Pharm. 2021 Nov;13(6):75-81. doi: 10.22159/ijap.2021v13i6.42815.

14. Tabassum R, Rizwan SH. Stability indicating analytical method development and validation for the estimation of ruxolitinib in bulk and pharmaceutical dosage form using UPLC. Int J Pharm Pharm Sci. 2023 Feb;15(2):40-6. doi: 10.22159/ijpps.2023v15i2.46839.

15. Dewi MK, Pratama R, Arifka M, Chaerunisaa A. Quality by design: approach to analytical method validation. Sciphar. 2022 Jun;1(1):38-46. doi: 10.58920/sciphar01010033.

16. Nunsavathu SN, Rajaganapathy K. A review on QBD approach in analytical method development and validation. IJPQA. 2024 Sep;15(3):1707-13. doi: 10.25258/ijpqa.15.3.93.

17. Xuan DT, Nguyen HM, Hoang VD. Recent applications of analytical quality by design methodology for chromatographic analysis: a review. Chemom Intell Lab Syst. 2024 Nov 15;254:105243. doi: 10.1016/j.chemolab.2024.105243.

18. Karnam S, Jindal AB, Paul AT. Implementing analytical quality by design in reversed-phase high-performance liquid chromatography for simultaneous estimation of teriflunomide and quercetin: applicability in dual drug-loaded topical microemulsion. J Liq Chromatogr Relat Technol. 2024 Mar;47(6-10):104-21. doi: 10.1080/10826076.2024.2325950.

19. Pharmaceutical Development International Conference on Harmonization (ICH); 2009;Q8(R2). Available from: https://database.ich.org/sites/default/files/q8_r2_guideline.pdf.

20. Quality Risk Management International Conference on harmonization (ICH). 2005. p. 9. Available from: https://database.ich.org/sites/default/files/q9_guideline.pdf.

21. Pharmaceutical quality system, International Conference on Harmonization (ICH). Vol. Q10; 2009. Available from: https://database.ich.org/sites/default/files/Q10%20Guideline.pdf.

22. Development and manufacture of drug substances International Conference on Harmonization (ICH). Vol. Q11; 2012. Available from: https://database.ich.org/sites/default/files/Q11%20Guideline.pdf.

23. Kumari N, Singh B, Saini G, Chaudhary A, Verma K, Vyas M. Quality by design: a systematic approach for the analytical method validation. J Drug Delivery Ther. 2019;9(3-s):1006-12. doi: 10.22270/jddt.v9i3-s.3114.

24. Yadav NK, Raghuvanshi A, Sharma G, Beg S, Katare OP, Nanda S. QBD-based development and validation of a stability indicating HPLC method for estimating ketoprofen in bulk drug and proniosomal vesicular system. J Chromatogr Sci. 2016 Oct;54(3):377-89. doi: 10.1093/chromsci/bmv151, PMID 26514627.

25. Validation of analytical procedures: text and Methodology International Conference on Harmonization (ICH). Vol. Q2(R1); 2005. Available from: https://database.ich.org/sites/default/files/q2%28r1%29%20guideline.pdf.

26. Narikimalli A, Galla R. A stability indicating UPLC method development and validation for the simultaneous estimation of nateglinide and metformin hydrochloride in bulk and tablet dosage form. Futur J Pharm Sci. 2023 Jun;9(1):55. doi: 10.1186/s43094-023-00503-2.

27. Validation of analytical procedures International Conference on Harmonization (ICH). Vol. Q2(R2); 2022. Available from: https://database.ich.org/sites/default/files/ich_q2-r2_document_step2_guideline_2022_0324.pdf.

28. Sonar P, Shaikh K, Harer S. Development and validation of novel RP-HPLC-DAD method for quantification of lapatinib ditosylate in newer nano-liposome formulation: a quality by design (QBD) approach. Int J App Pharm. 2022 Aug;14(6):239-50. doi: 10.22159/IJAP.2022V14I6.45750.

29. Hopkins AM, Kichenadasse G, Garrett Mayer E, Karapetis CS, Rowland A, Sorich MJ. Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab. Clin Cancer Res. 2020;26(13):3280-6. doi: 10.1158/1078-0432.CCR-19-2968, PMID 32086341.

30. Pauline LM, Karen AM, Leon A, Michiel SH, Alwin DR, Jos HB. A multiplex UPLC-MS/MS method for the quantification of three PD-L1 checkpoint inhibitors atezolizumab avelumab and durvalumab in human serum. 2024 Jun;15(243):116108. doi: 10.1016/j.jpba.2024.116108.

31. Subbarao Y, Pavani Y, Subbarao M. Simultaneous method development and validation of trastuzumab and hyaluronidase-Oysk and its pharmacokinetic studies with LC-MS/MS. J Pharm Sci Res. 2021 Feb;12(3):375-80.

32. Babu DC, Chetty CM, Mastanamma SK. Stability indicating RP-HPLC method development and validation for the estimation of atezolizumab in bulk and its injectable dosage form. J Pharm Res Int. 2017 Sep;18(5):1-9. doi: 10.9734/JPRI/2017/35615.

33. Kallam SD, Rudrapal M, Bodapati A. Simultaneous determination of atezolizumab and bevacizumab by LC–MS/MS in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2025 Jun;39(7):e70139. doi: 10.1002/bmc.70139, PMID 40525526.